农垦医学
農墾醫學
농은의학
AGRICULTURAL RECLAMATION MEDICINE
2014年
4期
297-299
,共3页
重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白%银屑病%阿维A
重組人Ⅱ型腫瘤壞死因子受體-抗體融閤蛋白%銀屑病%阿維A
중조인Ⅱ형종류배사인자수체-항체융합단백%은설병%아유A
rhTNFR-Fc%Psoriasis%Acitretin
目的:评价注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(商品名:益赛普)治疗中重度寻常型银屑病患者的疗效。方法:对我院2011年1月至2014年3月,诊断为中重度寻常型银屑病患者42例,其中益赛普组20例,阿维A组22例,按银屑病面积和严重程度指数(PASI)对疗效进行评分。结果:42例患者均完成治疗,治疗12周后,益赛普组PASI30、PASI60、PASI90的比例高于阿维A组,差异具有统计学意义(<0.05)。结论:抗肿瘤坏死因子靶向治疗中重度寻常型银屑病有效。
目的:評價註射用重組人Ⅱ型腫瘤壞死因子受體-抗體融閤蛋白(商品名:益賽普)治療中重度尋常型銀屑病患者的療效。方法:對我院2011年1月至2014年3月,診斷為中重度尋常型銀屑病患者42例,其中益賽普組20例,阿維A組22例,按銀屑病麵積和嚴重程度指數(PASI)對療效進行評分。結果:42例患者均完成治療,治療12週後,益賽普組PASI30、PASI60、PASI90的比例高于阿維A組,差異具有統計學意義(<0.05)。結論:抗腫瘤壞死因子靶嚮治療中重度尋常型銀屑病有效。
목적:평개주사용중조인Ⅱ형종류배사인자수체-항체융합단백(상품명:익새보)치료중중도심상형은설병환자적료효。방법:대아원2011년1월지2014년3월,진단위중중도심상형은설병환자42례,기중익새보조20례,아유A조22례,안은설병면적화엄중정도지수(PASI)대료효진행평분。결과:42례환자균완성치료,치료12주후,익새보조PASI30、PASI60、PASI90적비례고우아유A조,차이구유통계학의의(<0.05)。결론:항종류배사인자파향치료중중도심상형은설병유효。
Objective: To evaluate the effect of recombinant human tumor necrosis factor receptor(rhTNFR:Fc) in the treatment of moderate to severe plaque psoriasis on psoriasis area and severity index (PASI). Methods:Between January 2011 and March 2014,there were 42 cases of moderate to severe plaque psoriasis patients in the Affiliated Hospital of Shihezi university school of medicine, of which there were 20cases in trial group and 22 cases in the control group respectively, to evaluate the effect on PASI. Result: 42 cases of patients had accomplished the 12-week clinical trial. After 12 weeks the rate of PASI30、PASI60、PASI90 were significantly higher than those of the control group(P<0.05). Conclusion: The effect of rhTNFR-Fc is significant.